Liposomal Bupivacaine in Benign Soft Tissue Tumor Resection

Summary

Liposomal bupivacaine (Exparel) has been used as an adjunct to pain management in the perioperative setting. However, the efficacy of the drug has not bewen studied in patients with benign soft tissue tumor resections. The goal of the study is to see if Exparel controls pain and improves functional outcomes for patients after these procedures compared to the current standard Bupivacaine HCL.

Timeline

Start

2020-09-01

Primary completion

2022-09-01

Completion

2022-09-01

Drugs

Indications